IN THE NEWS
Best Stock Market News, September 2017
rHDL THERAPEUTICS is actively developing a novel nanoparticulate drug delivery platform capable of selectively targeting certain cell types for multiple disease indications including cancer and hepatitis.
rHDL Therapeutics, in partnership with a scientific team at MD Anderson Cancer Center and University of North Texas, is actively developing a novel nanoparticledrug delivery platform capable of selectively targeting certain cell types for multiple disease indications including cancer and liver disease. The technology has been successfully used to deliver therapeutic amounts of siRNA to different cancer cells, and promisingdata has been published in top tier peer reviewed publications. The company is pursuing aligned strategic collaborations for rapid development of this technology into clinical usage. TECHNOLOGY DETAILSThe technology involves a novel approach for the delivery of small interfering RNA (siRNA) and/or small molecule drugsto targeted cells by harnessing the body’s natural delivery vehicle –high density lipoproteins (HDLs). HDLs are essential components of the lipid transport system and play a pivotal role in reverse cholesterol transport. HDL particles are completely biodegradable, do not elicit immunologic responses, have long half-lives in circulation, and deliver lipids and micro RNA to certain cells through a receptor-mediated mechanism viascavenger receptor class B type 1 (SR-B1). A reconstituted form of HDL (rHDL) has been developed by the scientific team that mimicsthe human HDL particle. The rHDL particles have been shown to successfully deliverboth drugs and siRNA to target cells.
The rHDL technology is a platform technology that can deliver drugs and siRNA to cells expressing SR-B1 receptors. Since the drug/RNA is packagedinside the nanoparticle core, it isprotected from the body’s natural defense mechanisms and exhibitsprolongedcirculation time. Since many cancer cells constitutively overexpress SR-B1, rHDL technology offers a method to selectively deliver the payload to these cells. As an additional target, the liver also naturally expresses SR-B1, so our platform delivery vehicle could be used to treat a multitude of liver diseases, such as galactosemiaand fatty liver disease. Since it is a reconstituted form of a natural nanoparticle, toxicity issues from the particle itself arevery low. All these attributesmake it a promising approach forseveral diseases.
Our initial focus is ovarian cancer. Ovarian cancer is the leading cause of death from gynecological cancers worldwide, and is the fifth leading cause of cancer death in women. Ovarian cancer is almost invariably fatal, with high recurrence rates even after complete response to chemotherapy and debulking surgery. Recurrent tumors eventually become unresponsive to chemoradiation following an initial response. Our point of entry into the market will be ovarian cancer patients who have suffered a relapse following initial treatment.Additional indications we are actively pursuing are galactosemia (a rare metabolic disease) and a new therapy for fatty liver disease/non-alcoholic steatohepatitis.